Serum GDF15 level as predictive biomarker of clinical outcome in patients with unresectable hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy

QR Code

Serum GDF15 level as predictive biomarker of clinical outcome in patients with unresectable hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy

BackgroundHepatic arterial infusion chemotherapy (HAIC) using the FOLFOX regimen has been explored for unresectable hepatocellular carcinoma (HCC) patients, yet predictive biomarkers are lacking. This study aimed to evaluate the potential of serum growth differentiation factor 15 (GDF15) as a biomar...

Full description

Saved in:

Bibliographic Details
Main Authors:	Rui Xing, Junyu Gan, Jie Mei, Zhixiong Li, Jing Xu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Immunology
Subjects:	growth differentiation factor 15 hepatocellular carcinoma hepatic arterial infusion chemotherapy serum biomarker overall survival progression-free survival
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1619387/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Preoperative prognostic value of alfa-fetoprotein density in patients with hepatocellular carcinoma undergoing radiofrequency ablation
by: Bo-Wen Zhuang, et al.
Published: (2022-12-01)

Retrospective Multicentre Real-Life Study Evaluating the Efficacy of Atezolizumab Combined with Bevacizumab for the Treatment of Metastatic Hepatocellular Carcinoma: HIREAL Study
by: Barbe-Richaud JB, et al.
Published: (2025-07-01)

Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis
by: Yongfa Lei, et al.
Published: (2025-07-01)

Refining Intra-Arterial Therapy Selection for Large Hepatocellular Carcinoma: A Deep Learning Approach Based on Covariate Interaction Analysis
by: An C, et al.
Published: (2025-07-01)

Factor Analysis of the Effect of Hepatitis B-Related Liver Cancer Treatment Efficacy
by: Liu SW, et al.
Published: (2025-06-01)

Trajectories of Cancer Antigen 125 (CA125) Within 3 and 6 Months After the Initiation of Chemotherapy Treatment for Advanced Ovarian Cancer and Clinical Outcomes: A Secondary Analysis of Data from a Phase III Clinical Trial
by: Chang Yin, et al.
Published: (2025-07-01)

The incidence of malignant tumors in patients with liver cirrhosis and the impact of the development of hepatocellular carcinoma on the overall survival of patients with cirrhosis
by: Vladislav V. Petkau, et al.
Published: (2024-03-01)

The association between neutrophil percentage to albumin ratio and progression-free survival and overall survival in colorectal cancer patients: a retrospective cohort study
by: Hailun Xie, et al.
Published: (2025-07-01)

The role of Lobectomy in Glioblastoma management: A Retrospective series
by: Christina K. Arvaniti, et al.
Published: (2025-01-01)

THE MAIN PARAMETERS OF CELLULAR IMMUNITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER: RELATIONSHIP WITH EFFICIENCY OF CHEMOTHERAPY
by: A. I. Chertkova, et al.
Published: (2018-11-01)

Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02)
by: Hang Yuan, et al.
Published: (2025-07-01)

Hepatic Artery Infusion Chemotherapy for Hepatocellular Carcinoma: Clinical Advancements
by: Wei Xu, et al.
Published: (2025-05-01)

Survival outcomes after surgical resection of huge HCC (≥ 10 cm) with or without neoadjuvant hepatic arterial infusion chemotherapy
by: Chia-Ling Chiang, et al.
Published: (2025-06-01)

Transarterial Chemoembolization With or Without Systemic Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Comparative Study
by: Chengxiang Guo, et al.
Published: (2025-02-01)

Experience of using chemotherapy treatment for the first recurrence of ovarian cancer
by: V. N. Zhurman
Published: (2025-01-01)

EXPRESSION OF CANCER-TESTIS GENES PRAME, NY-ESO1, GAGE1, MAGE A3, MAGE A6, MAGE A12, SSX1, SLLP1, PASD1 IN PATIENTS WITH MULTIPLE MYELOMA, THEIR INFLUENCE ON OVERALL SURVIVAL AND RELAPSE RATE
by: A. A. Solodovnik, et al.
Published: (2018-07-01)

Hepatic Arterial Infusion Chemotherapy Combined Apatinib/Camrelizumab for Recurrent Hepatocellular Carcinoma After Hepatectomy
by: Zheng X, et al.
Published: (2025-06-01)

Profiles of survival prediction in glioblastoma
by: Franziska Loebel, et al.
Published: (2025-01-01)

Hepatic arterial infusion chemotherapy and sequential ablation treatment in large hepatocellular carcinoma
by: Huimin You, et al.
Published: (2022-12-01)

Predictive Value of the CA-125 Elimination Rate Constant K (KELIM) in Predicting Progression-Free Survival and Overall Survival in Epithelial Ovarian Cancer
by: Necim Yalcin, et al.
Published: (2025-07-01)

Clinical and economic analysis of treatment sequences with prolgolimab and BRAF/MEK inhibitors in adult patients with metastatic or unresectable cutaneous melanoma
by: S. K. Zyryanov, et al.
Published: (2024-02-01)

Survival of patients with bilateral renal cell cancer after nephro-preserving surgery
by: F. S. Ashyrova, et al.
Published: (2021-06-01)

Meta-analysis of the prognostic efficacy of daratumumab combined with standard therapy in high-risk multiple myeloma
by: Hongmei Zhou, et al.
Published: (2025-12-01)

Peculiarities of diagnostics and clinical course of different immunohistochemical subtypes of breast cancer.
by: M. Kh. El Khazhzh, et al.
Published: (2014-09-01)

Experience in the use of olaparib poly (ADP-ribose) polymerase inhibitors in maintenance therapy of BRCA-associated ovarian cancer
by: V. N. Zhurman, et al.
Published: (2023-02-01)

Comparative long-term outcomes of first-line CDK4/6 inhibitors plus endocrine therapy versus endocrine therapy in patients with HR+/HER2-metastatic or advanced breast cancer: a meta-analysis
by: Xiaojian Wang, et al.
Published: (2025-07-01)

Relationship Between Best Tumor Shrinkage and Progression‐Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [177Lu]Lu‐DOTA‐TATE: Ad Hoc Analysis of the Phase III NETTER‐1 Trial
by: Marianne Pavel, et al.
Published: (2025-05-01)

Oxidative Stress Score as a Simplified Surrogate for Prognostic Stratification and Therapeutic Decision-Making in Multiple Myeloma
by: Qi Liang, et al.
Published: (2025-06-01)

Predicting recurrence and recurrence-free survival in initially unresectable hepatocellular carcinoma: a novel nomogram for patients undergoing conversion hepatectomy with lenvatinib, PD-1 inhibitor, and interventional therapy
by: Cheng Xu, et al.
Published: (2025-07-01)

Long-term results of liver transplantation for hepatocellular carcinoma
by: M. Sh. Khubutia, et al.
Published: (2018-08-01)

Lenvatinib in advanced radioiodine-refractory differentiated thyroid cancer: what’s new?
by: E. V. Borodavina, et al.
Published: (2024-12-01)

Hepatic arterial infusion chemotherapy versus systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a meta-analysis of survival outcomes
by: Di Zeng, et al.
Published: (2025-07-01)

Classification of microvascular invasion of hepatocellular carcinoma: Different standards, common goals: Letter to the editor on “Classification of microvascular invasion of hepatocellular carcinoma: Correlation with prognosis and magnetic resonance imaging”
by: Wei Chen, et al.
Published: (2025-07-01)

Adjuvant Hepatic Arterial Infusion Chemotherapy Versus Transarterial Chemoembolization for Preventing Early Recurrence After Surgical Resection in Hepatocellular Carcinoma
by: Xia Y, et al.
Published: (2025-07-01)

Survival of retinoblastoma patients: a cohort study by two Russian medical centers
by: S. V. Saakyan, et al.
Published: (2021-03-01)

Estimating long-term overall survival with olaparib as maintenance therapy in patients with newly diagnosed advanced ovarian cancer with BRCA mutations
by: N. A. Avxentyev, et al.
Published: (2021-10-01)

High-dose versus Standard-dose Daunorubicin in Induction Chemotherapy for Acute Myeloid Leukemia: A Meta-Analysis
by: Bibi Kulsoom, et al.
Published: (2025-06-01)

Analysis of the effect of clinical and laboratory parameters on survival in patients with metastatic renal cell cancer with intermediate prognosis according to IMDC (International mRCC Database Consortium)
by: D. V. Semenov, et al.
Published: (2023-07-01)

Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
by: Emilie Adrian Christiansen, et al.
Published: (2024-12-01)

The influence of some clinical and morphological prognosis factors on the 5-year survival of patients with stage I cervical cancer
by: E. V. Makarova, et al.
Published: (2019-12-01)